3/24/2008 6:39:22 PM
Generic Pharmaceutical Association President and CEO Kathleen Jaeger today issued the following statement on the introduction of the “Pathway to Biosimilars Act” (H.R. 5629): “‘The Pathway for Biosimilars Act’ is a pathway to the wrong destination for patients in need of safe and affordable biogenerics. This new bill, at best, is a disappointing distraction that does nothing to advance legislation. At worst, it’s a step backwards that puts brand company profits before patient needs. For a pathway to work, it must ensure patient access. Unfortunately, this new proposal creates a pathway filled with needless roadblocks to access.
comments powered by